English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 16.74 |
| Open | 16.52 |
| 1-Year Change | 6.51% |
| Day's Range | 15.68 - 16.67 |
Phibro Animal Health Corporation is a global diversified animal health and mineral nutrition company. The Company operates in three segments, which include Animal Health, Mineral Nutrition and Performance Products. The Company develops, manufactures and markets a range of products for food animals, including poultry, swine, beef and dairy cattle, and aquaculture. The Company sells animal health and mineral nutrition products either directly to integrated poultry, swine and cattle producers or through commercial animal feed manufacturers, wholesalers and distributors. Its Medicated Feed Additives (MFAs) and other business consist of concentrated medicated products, which are administered through animal feeds. The Company's MFAs and other business consists of the production and sale of antibacterials, including Stafac, Terramycin, Neo-Terramycin and Mecadox and anticoccidials, including Nicarb, Aviax, Aviax Plus, Coxistac and amprolium.
BRIEF: For the six months ended 31 December 2021, Phibro Animal Health Corp revenues increased 11% to $447.4M. Net income decreased 4% to $24M. Revenues reflect Animal Health segment increase of 10% to $291.9M, Mineral Nutrition segment increase of 15% to $121.1M, United States segment increase of 10% to $265.5M, Latin America and Canada segment increase of 16% to $90.7M. Net income was offset by Selling.
Common Stock $.10 Par, 5/06, 30,300 auth., Class A 12,600 issd. Class B 11,888.50. issd. Series A Preferred Stock $100 Par, 9/05, 5,207 auth., 5,207 issd.
